CAMBRIDGE, Mass.--Variagenics, a privately held venture-backed drug discovery technology company here, announced the appointment of four pharmacogenomics directors.
Mark Adams, previously the bioinformatics director for Alphagene, will be Variagenics' director of bioinformatics. Patrice Rioux, formerly medical director for Biogen, is Variagenics' new director of clinical pharmacogenomics. Troy Norris, also formerly of Biogen, where he was responsible for research and development program prioritization, is now senior director of business development for pharmacogenomics. And Andrew Ferrie joins Variagenics as director of variance detection from his former position as gene discovery manager at Human Genome Sciences.
"Variagenics' core competency is in the rapid discovery and analysis of genetic variation using our proprietary Variance Scanning and Variance Imaging technologies," said Fred Ledley, Variagenics' CEO. The appointments move the company toward its goal of applying genetic variation to the discovery and development of new pharmaceuitcal products, he said.